Sp723
USE OF CONCOMITANT MEDICATIONS IN IBD- EVIDENCE, OUTCOMES AND RISKS
Date
May 20, 2024
Presenter
Tracks
Related Products
ANTI-TNF IN COMBINATION WITH LOW DOSE METHOTREXATE OUTPERFORMS ANTI-TNF MONOTHERAPY IN PATIENTS WITH PEDIATRIC CROHN'S DISEASE INITIATING ADALIMUMAB BUT NOT INFLIXIMAB
BACKGROUND: Tumor necrosis factor inhibitors (TNFi) are a mainstay of pediatric Crohn’s disease (PCD) therapy; yet not all patients respond, and others lose response over time. Combination therapy with methotrexate may improve response; however, this has not been rigorously evaluated…
A PROSPECTIVE, MULTI-INSTITUTIONAL STUDY REVEALS THE COMBINATION OF RNA ANALYSIS WITH DNA-BASED NEXT-GENERATION SEQUENCING (NGS) IMPROVES THE PREOPERATIVE CLASSIFICATION OF PANCREATIC CYSTS AND IDENTIFICATION OF ADVANCED NEOPLASIA
BACKGROUND: As outlined by the Kyoto guidelines, targeted DNA-based NGS of pancreatic cyst fluid (PCF) is an important adjunct to the evaluation of pancreatic cyst patients…
CLOSTRIDIOIDES DIFFICILE INFECTION INDUCES A PRO-STEATOTIC AND PRO-INFLAMMATORY METABOLIC STATE IN LIVER
BACKGROUND: Recent studies suggest links between _Clostridioides difficile_ infection (CDI) and liver disorders, with non-alcoholic fatty liver disease (NAFLD) increasing CDI risk and CDI exacerbating the progression and prognosis of liver cirrhosis. Moreover, gut dysbiosis, often leading to _C…
